Drugs for Esophageal Varix (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 62)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ethiodized oil |
Approved, Investigational |
Phase 4 |
|
8008-53-5 |
|
Synonyms:
|
2 |
|
Ethanolamine oleate |
Approved |
Phase 4 |
|
2272-11-9 |
|
Synonyms:
Ethamolin
Ethanolamine oleate
Monoethanolamine oleate
Monoethanolamini oleas
|
Oldamin
Oleate de monoethanolamine
Oleato de monoetanolaminio
|
|
3 |
|
Terlipressin |
Approved, Investigational |
Phase 4 |
|
14636-12-5 |
72081 |
Synonyms:
(2S)-6-Amino-2-({[(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-{[2-({2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-13-benzyl-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-N-[(C-hydroxycarbonimidoyl)methyl]hexanimidate
Glipressin
Gly gly gly 8 lys vasopressin
Glycylpressin
Gly-gly-gly-8-lys-vasopressin
Glypressin
N-(alpha)-Glycyl-glycyl-glycyl-8-lysine vasopressin
N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin
Remestyp
SID124896640
Terlipresina
Terlipressin
|
TERLIPRESSIN ACETATE
TERLIPRESSINA
TERLIPRESSINE
TERLIPRESSINUM
Terlypressin
TGLVP
Tri-gly-8-lys- vasopressin
Triglycyl lysine vasopressin
Triglycyl-(8-lysine)vasopressin
Triglycylvasopressin
VARIQUEL
|
|
4 |
|
Somatostatin |
Approved, Investigational |
Phase 4 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
5 |
|
Octreotide |
Approved, Investigational |
Phase 4 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
6 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
7 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
8 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
9 |
|
Retinol palmitate |
|
Phase 4 |
|
|
|
10 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
11 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
12 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
13 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
14 |
|
Rifaximin |
Approved, Investigational |
Phase 2, Phase 3 |
|
80621-81-4 |
46783403 6436173 |
Synonyms:
(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,23,36-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6-oxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1,.0,.0,.0,]heptatriaconta-1(35),2,4,9,19,21,23,25(36),26(34),28,30,32-dodecaen-13-yl acetic acid
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
NORMIX
Redactiv
RIFACOL
RIFAMYCIN L 105
RIFAMYCIN L 105SV
RIFAXIDIN
Rifaximin
|
RIFAXIMINA
RIFAXIMINE
RIFAXIMINUM
RIFAXIMINUN
TARGAXAN
Xifaxan
XIFAXANTA
XIFAXSAN
|
|
15 |
|
Warfarin |
Approved |
Phase 3 |
|
81-81-2, 129-06-6 |
54678486 |
Synonyms:
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine
(S)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
200 Coumarin
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin
3-(Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin
3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin
4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin
4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine
4oh-Coumarin deriv.
aldo Brand OF warfarin sodium
Aldocumar
Antigen brand OF warfarin sodium
Apotex brand OF warfarin sodium
apo-Warfarin
Arab rat death
Arab rat deth
Athrombin
Athrombine-K
Athrombin-K
Bailly brand OF warfarin sodium
Boots brand OF warfarin sodium
Bristol-myers squibb brand OF warfarin sodium
Brumolin
Choice
Compound 42
CO-Rax
Coumadin
Coumadin Tabs
Coumadin®|Marevan®|panwarfin
Coumadine
Coumafen
Coumafene
Coumaphen
Coumaphene
Coumarins
Coumefene
Cov-R-tox
D-CON
delta-CON
Dethmor
Dethnel
Dicusat e
DL-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
Eastern states duocide
Estedi brand OF warfarin sodium
fasco Fascrat powder
Frass-ratron
Genpharm brand OF warfarin sodium
Gen-warfarin
Goldshield brand OF warfarin sodium
Jantoven
Killgerm sewarin P
Kumader
Kumadu
Kumatox
Kypfarin
Latka 42
Liqua-tox
Maag rattentod cum
Marevan
|
Mar-frin
Martin'S mar-frin
Maveran
Mouse pak
NSC-59813
PANWARFIN
Place-pax
Potassium, warfarin
Prothromadin
Rat & mice bait
Rat and mice bait
Rat-alpha-way
Rat-a-way
Rat-beta-gon
Rat-b-gon
Rat-gard
Rat-kill
Rat-mix
Rat-O-cide #2
Rat-O-cide no. 2
Rat-ola
Ratorex
Ratox
Ratoxin
Ratron
Ratron g
Rats-NO-more
Ratten-koederrohr
Rattenstreupulver neu schacht
Rattenstreupulver new schacht
Rattentraenke
Rat-trol
Rattunal
RAX
RCR Grey squirrel killer concentrate
Rodafarin
Rodafarin c
ro-Deth
Rodex
Rodex blox
Rosex
Rough & ready mouse mix
Rough and ready mouse mix
Sakarat
Sewarin
Sodium, warfarin
Sofarin
Solfarin
Sorexa plus
Spray-trol brand roden-trol
Tedicumar
Temus W
Tintorane
Tox-hid
Twin light rat away
Vampirinip II
Vampirinip III
Waran
Warf 42
Warfant
Warfarat
WARFARIN
Warfarin Plus
Warfarin potassium
Warfarin Q
Warfarin sodium
Warfarina
Warfarine
Warficide
Warfilone
Zoocoumarin
|
|
16 |
|
Simvastatin |
Approved |
Phase 3 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
17 |
|
Nitric Oxide |
Approved |
Phase 3 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(NO)(.)
[NO]
EDRF
Endogenous nitrate vasodilator
Endothelium-derived nitric oxide
Endothelium-derived relaxing factor
HYDROXYAMINE
INOmax
INOmax®|nitric oxide|nitrogen monoxide
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, nitrogen
Monoxido de nitrogeno
Monóxido de nitrógeno
Monoxyde d'azote
Nitrate vasodilator, endogenous
NITRIC OXIDE
Nitric oxide, endothelium derived
Nitric oxide, endothelium-derived
Nitrogen monooxide
|
Nitrogen monoxide
Nitrogen oxide
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
NO(.)
OHM-11771
Oxide, nitric
Oxido de nitrogeno(II)
óxido de nitrógeno(II)
Oxido nitrico
óxido nítrico
Oxyde azotique
Oxyde nitrique
Stickstoff(II)-oxid
Stickstoffmonoxid
Vasodilator, endogenous nitrate
|
|
18 |
|
Carvedilol |
Approved, Investigational |
Phase 2, Phase 3 |
|
72956-09-3 |
2585 |
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
14C-Labeled carvedilol
Artist
BM 14.190
BM-14.190
BM-14190
BM-14-190
C07AG02
CARVEDILOL
Carvédilol
Carvedilol hydrochloride
Carvedilol, (-)
Carvedilol, (-)-isomer
Carvedilol, (+)
Carvedilol, (+)-isomer
Carvedilol, (+-)-isomer
Carvedilol, (R)-isomer
Carvedilol, (S)-isomer
Carvedilol, 14C labeled
|
Carvedilol, 14C-labeled
Carvedilolum
Carvedilolum [Latin]
Coreg
COREG CR
Coreg®|DQ 2466|Eucardic®|SKF 105517
Coropres
Dilatrend
DQ 2466
DQ-2466
Eucardic
EUCARDIC 12.5
EUCARDIC 25
EUCARDIC 3.125
EUCARDIC 6.25
Kredex
Querto
SKF 105517
SKF-105517
|
|
19 |
|
Propranolol |
Approved, Investigational |
Phase 3 |
|
318-98-9, 525-66-6 |
62882 4946 |
Synonyms:
(+-)-1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-NAPHTHYLOXY)-2-HYDROXY-3-ISOPROPYLAMINOPROPANE HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHOXY)-PROPAN-2-OL HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-(Isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-ISOPROPYLAMINO-3-(1-NAPHTHOXY)-PROPAN-2-OL-HYDROCHLORIDE
Anaprilin
Anapriline
ANGILOL
APSOLOL
Avlocardyl
AY-64043
AY-64043-
BEDRANOL
BEDRANOL S.R.
Bedranol®|Hemangiol®|Inderal®|propranolol hydrochloride
Beprane
BERKOLOL
Betachron
Betadren
BETADUR CR
Betalong
Beta-Neg
BETA-PROGRANE MR
beta-Propranolol
Beta-Tablinen
Beta-Timelets
b-Propranolol
CARDINOL
Caridolol
Corpendol
Deralin
Dexpropranolol
Dl-Propranolol Hydrochloride
Dociton
DUPROMEX
Duranol
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HALF BETA-PROGRANE MR
HALF PROPANIX LA
HALF PROPATARD LA
HALF-BEPRANE CR
HALF-BETADUR CR
HALF-INDERAL LA
HEMANGEOL
Hydrochloride, propranolol
ICI-45520
Inderal
INDERAL LA
|
Inderide
INDERIDE-40/25
INDERIDE-80/25
Indobloc
INNOPRAN
INNOPRAN XL
Intermigran
Kemi S
LEDERPRONOL
LOPRANOL LA
Migrastat
NSC-91523
Obsidan
Obzidan
Oposim
Prano-Puren
PROBETA LA
Propanalol
Propanix
PROPANIX LA
PROPANIX-10
PROPANIX-160
PROPANIX-160 SR
PROPANIX-40
PROPANIX-80
Propanolol
PROPATARD LA
Prophylux
Propranalol
PROPRANOLOL
PROPRANOLOL HCL
Propranolol Hcl Intensol
Propranolol hydrochloride
PROPRANOLOL HYDROCHLORIDE INTENSOL
Propranololo
Propranololum
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
RAPRANOL SR
Rapynogen
Reducor
Reducor Line
Rexigen
SAGITTOL
Servanolol
SLO-BLOK
SLO-PRO
SLOPROLOL
Sumial
SYPROL
TESNOL
Î’-propranolol
|
|
20 |
|
Nadolol |
Approved |
Phase 3 |
|
42200-33-9 |
39147 |
Synonyms:
Corgard
Corgard®|corzide|SQ-11725
CORZIDE
|
|
|
21 |
|
Vapreotide |
Experimental, Investigational |
Phase 3 |
|
103222-11-3 |
23725064 70689318 71306 |
Synonyms:
BMY 41606
BMY 41606|CCRIS 6495|RC 160|RC-160|Sanvar®|vapreotide acetate
BMY-41606
DP-05-094
Octastatin
RC-160
|
SANVAR
Vapreotida
Vapreotide
Vapreotide acetate
Vapreotidum
|
|
22 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Sclerosing Solutions |
|
Phase 3 |
|
|
|
25 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
26 |
|
Fibrin Tissue Adhesive |
|
Phase 3 |
|
|
|
27 |
|
Hemostatics |
|
Phase 3 |
|
|
|
28 |
|
Coagulants |
|
Phase 3 |
|
|
|
29 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
30 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
31 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
32 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
33 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
34 |
|
Analgesics |
|
Phase 3 |
|
|
|
35 |
|
Ulipristal acetate |
|
Phase 3 |
|
126784-99-4 |
13559282 130904 |
Synonyms:
(11BETA,17ALPHA)-17-ACETYL-11-[4-(DIMETHYLAMINO)PHENYL]-3-OXOESTRA-4,9-DIEN-17-YL ACETATE
14-Acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-1,6-dien-14-yl acetic acid
17-ACETOXY-11-(4-N,N-DIMETHYLAMINOPHENYL)PREGNA-4,9-DIENE-3,20-DIONE
CDB 2914
CDB-2914
CDB-2914|EllaOne®|VA2914
ELLA
ELLAONE
|
ESMYA
PGL-4001
RTI-3021-012
ULIPRISTAL ACET
ULIPRISTAL ACETATE
Ulipristal acetic acid
VA2914
VA-2914
|
|
36 |
|
Antihypertensive Agents |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Adrenergic alpha-Antagonists |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
40 |
|
Calcium, Dietary |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
calcium channel blockers |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Antioxidants |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Protective Agents |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
45 |
|
Adrenergic beta-Antagonists |
|
Phase 3 |
|
|
|
46 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
47 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
48 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
49 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
50 |
|
Calcium |
Nutraceutical |
Phase 2, Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show top 50)
(show all 76)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices |
Unknown status |
NCT04074473 |
Phase 4 |
propranolol |
2 |
Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices |
Unknown status |
NCT02740166 |
Phase 4 |
propranolol |
3 |
Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection |
Completed |
NCT00799851 |
Phase 4 |
cyanoacrylate injection |
4 |
Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial |
Completed |
NCT02119884 |
Phase 4 |
Terlipressin;Octreotide |
5 |
Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices |
Completed |
NCT00534677 |
Phase 4 |
Terlipressin;Octreotide |
6 |
PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL |
Completed |
NCT01893541 |
Phase 4 |
PROPRANOLOL |
7 |
Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices |
Completed |
NCT01291277 |
Phase 4 |
|
8 |
Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed |
Completed |
NCT00369694 |
Phase 4 |
Terlipressin;Terlipressin & then Dummy |
9 |
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension |
Completed |
NCT01059396 |
Phase 4 |
propranolol;carvedilol;placebo |
10 |
A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding |
Completed |
NCT01112852 |
Phase 4 |
pantoloc 40 mg;somatostatin or terlipressin |
11 |
Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study |
Recruiting |
NCT03624517 |
Phase 4 |
Octreotide |
12 |
Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices |
Recruiting |
NCT01970748 |
Phase 4 |
Propranolol |
13 |
Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed: A Randomized Controlled Study |
Not yet recruiting |
NCT05199038 |
Phase 4 |
Octreotide |
14 |
Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices |
Unknown status |
NCT01897051 |
Phase 2, Phase 3 |
Rifaximin + propranolol;Propranolol + Placebo |
15 |
Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol |
Unknown status |
NCT02508623 |
Phase 3 |
Rifaximin;Placebo |
16 |
Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices |
Unknown status |
NCT03388125 |
Phase 3 |
Injection Sclerotherapy;N-butyl-2-cyanoacrylate |
17 |
A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy |
Unknown status |
NCT01618890 |
Phase 3 |
|
18 |
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV) |
Unknown status |
NCT02853526 |
Phase 3 |
Propranolol;Warfarin |
19 |
Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices |
Completed |
NCT00493480 |
Phase 3 |
carvedilol;propranolol |
20 |
Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices |
Completed |
NCT00161915 |
Phase 3 |
Fibrin Sealant |
21 |
Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy |
Completed |
NCT02134626 |
Phase 3 |
Simvastatin;Placebo pill |
22 |
The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension |
Completed |
NCT00331188 |
Phase 3 |
Sanvar® (vapreotide) |
23 |
A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding |
Completed |
NCT01095185 |
Phase 3 |
Simvastatin;Placebo |
24 |
Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial |
Completed |
NCT01242280 |
Phase 3 |
|
25 |
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis |
Recruiting |
NCT04365868 |
Phase 2, Phase 3 |
belapectin;Placebo |
26 |
Randomized Controlled Trial of Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding in Cirrhotic Patients With Arterial Hypertension |
Recruiting |
NCT04499898 |
Phase 2, Phase 3 |
Carvedilol |
27 |
Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding |
Terminated |
NCT00409084 |
Phase 3 |
|
28 |
Randomized Study Comparing Ligation With Propranolol for Primary Prophylaxis of Variceal Bleeding in Candidates for Liver Transplantation |
Terminated |
NCT00337740 |
Phase 3 |
propranolol |
29 |
A New Technique to Enhance Detection of Small Esophageal Varices by PillCam ESO Capsule Endoscopy |
Withdrawn |
NCT00911131 |
Phase 3 |
|
30 |
Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis |
Completed |
NCT01188733 |
Phase 1, Phase 2 |
Long acting octreotide 10mg;Long acting Octreotide 30mg;Saline |
31 |
Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy |
Completed |
NCT01851252 |
Phase 1 |
|
32 |
Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices; Multicenter Study |
Unknown status |
NCT02256046 |
|
|
33 |
Magnetic-assisted Capsule Endoscope System With or Without 3D Images in Esophageal Varices Detection Compared With Conventional Esophagogastroduodenoscopy in Cirrhotic Patients |
Unknown status |
NCT04588974 |
|
|
34 |
A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis |
Unknown status |
NCT01212250 |
|
carvedilol;Placebo |
35 |
Optimal Time for Follow up After Variceal Band Ligation in Cirrhotic Patients: a Randomized Trial |
Unknown status |
NCT04602663 |
|
|
36 |
A Single-center Randomized Controlled Study of Secondary Prophylaxis of Cirrhosis Related Esophagogastric Variceal Hemorrhage Treated With HVPG-guided Therapy or Standard Esophageal Variceal Ligation Plus Beta-blocker |
Unknown status |
NCT03687216 |
|
|
37 |
Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy. |
Unknown status |
NCT02767206 |
|
|
38 |
Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding |
Unknown status |
NCT03212872 |
|
|
39 |
Investigator Sponsored Study of Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices |
Unknown status |
NCT01426087 |
|
Somatostatin |
40 |
Efficacy of Nonselective Beta Blockers vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices |
Completed |
NCT02583698 |
|
Carvedilol;Placebo |
41 |
Early Primary Prophylaxis With Beta-Blockers In Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: A Randomized Controlled Trial |
Completed |
NCT00772057 |
|
Propranolol;Placebo |
42 |
Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis |
Completed |
NCT04210297 |
|
|
43 |
San Diego Bleeding Esophageal Varices Study |
Completed |
NCT00690027 |
|
|
44 |
Evaluation of the PillCamâ„¢ Eso Capsule in the Detection of Esophageal Varices |
Completed |
NCT00481416 |
|
|
45 |
Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study |
Completed |
NCT02593799 |
|
|
46 |
A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices |
Completed |
NCT02465645 |
|
Carvedilol;Carvedilol + Simvastatin |
47 |
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study |
Completed |
NCT03583996 |
|
|
48 |
Transparent Cap-assisted Endoscopic Sclerotherapy(Lauromacrogol Injection) in Esophageal Varices: a Randomized Controlled Trial |
Completed |
NCT02361593 |
|
|
49 |
Noninvasive Tests to Predict the Presence of Esophageal Varices in Patients With Liver Cirrhosis |
Completed |
NCT03513887 |
|
|
50 |
A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis. |
Completed |
NCT01196507 |
|
Carvedilol;Placebo |
|